Clinical Trial Update: Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy [Phase 3]

View source ↗

Summary

Phase 3 clinical trial comparing Exenatide with insulin glargine in Type 2 diabetes patients for whom insulin therapy is appropriate. The study status is comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• BYETTA (Exenatide)
• Lantus (insulin glargine)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED